Coherus Oncology (CHRS)
Healthcare · Biotechnology
1 member of Congress has disclosed 1 trade in Coherus Oncology (CHRS) since 2023: 0 buys and 1 sale. The most recent was disclosed on Feb 9, 2023.
- Trades disclosed
- 1
- Members trading
- 1
- Buys / sells
- 0 / 1
- Reported value
- $15K–$50K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at CHRS
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
No matching research items have been collected yet. Coverage is growing; an empty result does not mean there has been no activity.
Who traded CHRS
- Rep. Shri Thanedar (D-MI-13)0 buys · 1 sale01Feb 9, 2023
All trades
- Feb 9, 2023$15K–$50K
Rep. Shri Thanedar (D-MI-13)
$15K–$50K · Traded Jan 23, 2023 · disclosed Feb 9, 2023
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.